New cancer drug WTX-330 enters human testing for advanced tumors
NCT ID NCT06939283
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug works against the cancer. Researchers will monitor side effects, tumor shrinkage, and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WTX-330
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers or lymphoma that have not responded to standard therapies.
- What could go wrong
- This is an early, small trial (100 participants) focused on safety and dosing, so it is uncertain whether WTX-330 will effectively shrink tumors or improve survival. Side effects are possible and being closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Could a Two-Drug combo reawaken the immune system against resistant cancers?